This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;10(7):455-63.
doi: 10.1016/S1473-3099(10)70093-1.

Effect of treating co-infections on HIV-1 viral load: a systematic review

Affiliations

Effect of treating co-infections on HIV-1 viral load: a systematic review

Kayvon Modjarrad et al. Lancet Infect Dis. 2010 Jul.

Abstract

Co-infections contribute to HIV-related pathogenesis and often increase viral load in HIV-infected people. We did a systematic review to assess the effect of treating key co-infections on plasma HIV-1-RNA concentrations in low-income countries. We identified 18 eligible studies for review: two on tuberculosis, two on malaria, six on helminths, and eight on sexually transmitted infections, excluding untreatable or non-pathogenic infections. Standardised mean plasma viral load decreased after the treatment of co-infecting pathogens in all 18 studies. The standardised mean HIV viral-load difference ranged from -0.04 log(10) copies per mL (95% CI -0.24 to 0.16) after syphilis treatment to -3.47 log(10) copies per mL (95% CI -3.78 to -3.16) after tuberculosis treatment. Of 14 studies with variance data available, 12 reported significant HIV viral-load differences before and after treatment. Although many of the viral-load reductions were 1.0 log(10) copies per mL or less, even small changes in plasma HIV-RNA concentrations have been shown to slow HIV progression and could translate into population-level benefits in lowering HIV transmission risk.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

We declare that we have no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart of study selection
Figure 2
Figure 2. Changes in HIV-1 RNA concentration (log10 copies per mL) after treatment of co-infection (18 studies)
*For the four studies without variance data published or provided,,,, SMDs and 95% CIs were calculated on the basis of the average variability found in the other studies. SMD=standardised mean difference.

Comment in

References

    1. WHO. Progress report. Geneva: World Health Organization; 2009. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector.
    1. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 1993;262:1011–1018. - PubMed
    1. Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther. 2003;8:72–75. - PubMed
    1. Stein DS. Herpes virus infections, HIV, and disease progression. AIDS Clin Care. 1995;7:11–14. 18. - PubMed
    1. Webster A. Cytomegalovirus as a possible cofactor in HIV disease progression. J Acquir Immune Defic Syndr. 1991;4 suppl 1:S47–S52. - PubMed

Publication types

MeSH terms

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite

AltStyle によって変換されたページ (->オリジナル) /